The novel device includes a curved needle and graded openings along the needle shaft, allowing for increased distribution of cells.
The result is maximized retention of stem cells to repair the heart.
"Although biotherapies are increasingly more sophisticated, the tools for delivering regenerative therapies demonstrate a limited capacity in achieving high cell retention in the heart. Retention of cells is, of course, crucial to an effective, practical therapy." said Atta Behfar, M.D., Ph.D., a Mayo Clinic cardiology specialist and leading author of the study.
Researchers from the Mayo Clinic Center for Regenerative Medicine in Rochester and Cardio3 Biosciences in Mont-Saint-Guibert, Belgium, collaborated to develop the device, beginning with computer modeling in Belgium. Once refined, the computer-based models were tested in North America for safety and retention efficiency.
What's the significance?
- The new curved catheter eliminates backflow and limits loss of cells
- Graded small to large side holes limit pressures in the heart to keep cells targeted
- The design has proved to be more effective in both healthy and damaged hearts
This new catheter is being used in the European CHART-1 clinical trials, now underway. This is the first Phase III trial to regenerate hearts of patients who have suffered heart attack damage. The studies are the outcome of years of basic science research at Mayo Clinic and earlier clinical studies with Cardio3 BioSciences and Cardiovascular Centre in Aalst, Belgium, conducted between 2009 and 2010.
- Behfar A, Latere JP, Bartunek J, Homsy C, Daro D, Crespo-Diaz RJ, Stalboerger PG, Steenwinckel V, Seron A, Redfield MM, & Terzic A (2013). Optimized Delivery System Achieves Enhanced Endomyocardial Stem Cell Retention. Circulation. Cardiovascular interventions PMID: 24326777